<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169182</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2000-01</org_study_id>
    <nct_id>NCT00169182</nct_id>
  </id_info>
  <brief_title>Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma</brief_title>
  <official_title>Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare two regimen of chemotherapy used as first treatment
      for patients with larynx or hypopharynx tumors that would be treated with total laryngectomy.
      The standard treatment is a combination of 2 drugs (Cisplatin and 5FU). The aim of the study
      is to evaluate the potential benefit of the addition of a third drug (Docetaxel) in the
      chemotherapy regimen. Patients will receive 3 cycles of chemotherapy. Responders to the
      induction treatment are treated with radiation with a purpose of larynx preservation. Non
      responders patients will be treated with total laryngectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to compare two regimen of induction chemotherapy for patients
      with T3 and T4 larynx or hypopharynx carcinoma that would be treated with total laryngectomy.
      The aim of the study is to compare the standard regimen (Cisplatin + 5FU) versus the TPF
      regimen (Taxotere + Cisplatin + 5FU). Responders to the induction treatment are treated with
      radiation with a purpose of larynx preservation. Non responders patients will be treated with
      total laryngectomy followed by postoperative radiation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2001</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-years larynx preservation rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-years survival rate</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Larynx Cancer</condition>
  <condition>Hypopharynx Cancer</condition>
  <arm_group>
    <arm_group_label>TPF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel, Cisplatine, 5-FU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatine, 5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOCETAXEL</intervention_name>
    <description>75 mg/m 2 on day 1</description>
    <arm_group_label>TPF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m 2 on day 1</description>
    <arm_group_label>PF</arm_group_label>
    <arm_group_label>TPF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluoro-3-Pyridinecarboxylic Acid</intervention_name>
    <description>750 mg/m 2 by 24-hour continuous infusion for 5 days</description>
    <arm_group_label>PF</arm_group_label>
    <arm_group_label>TPF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T3 and T4 larynx and hypopharynx tumor that would be treated with total laryngectomy

          -  Biopsy proven carcinoma

          -  Adequate biology

          -  Performance status 0 or 1

        Exclusion Criteria:

          -  Larynx or hypopharynx tumors that could be treated with partial laryngectomy

          -  Distant metastasis

          -  Prior surgery, chemotherapy or radiation

          -  Intercurrent disease that is a contra indication to chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Calais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bretonneau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gortec.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Larynx cancer</keyword>
  <keyword>Hypopharynx cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Randomized trial</keyword>
  <keyword>Larynx preservation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

